<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895089</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS98-CT2-20</org_study_id>
    <nct_id>NCT00895089</nct_id>
  </id_info>
  <brief_title>Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess</brief_title>
  <official_title>Prospective, Randomized, Open-Labeled, Active-Controlled Comparison of Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares the use of moxifloxacin versus ceftriaxone in the treatment of
      primary pyogenic liver abscess. The trial will include nonpregnant adults presenting with
      primary liver abscess based on clinical diagnosis and computed tomography. The trial aims to
      determine whether the use of moxifloxacin can effectively treat primary pyogenic liver
      abscess and shorten hospitalization. This regimen has the additional benefit of avoiding
      nephrotoxic agents, such as aminoglycosides, used frequently in treatment of pyogenic liver
      abscess. Development of antibiotic resistance to colonized bacteria in the gastrointestinal
      tract will also be evaluated using stool cultures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment efficacy</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Day 3, 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and radiological response</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality attributable to liver abscess during treatment</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of complication (metastatic infections to the central nervous system and/or eyes)</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of gastrointestinal colonization of Klebsiella pneumoniae in patients and rates of resistance post-antibiotic use.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Liver Abscess</condition>
  <arm_group>
    <arm_group_label>A: Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin 400mg IV once daily for 14 days, then 400mg PO once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Ceftriaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ceftriaxone 2gm IV every 12 hours for 14 days, then cephalexin 1gm PO every 6 hours for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin (Avelox)</intervention_name>
    <description>moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week</description>
    <arm_group_label>A: Moxifloxacin</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <description>ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week</description>
    <arm_group_label>B: Ceftriaxone</arm_group_label>
    <other_name>Rocephin</other_name>
    <other_name>Cefin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater or equal to 20 years.

          -  Clinical diagnosis of liver abscess, supported by an abdominal CT scan, documenting
             the presence of liver abscess, in the absence of biliary tract stones (except for
             gallstones without biliary tract dilatation), biliary tract dilatation and biliary
             tract tumors. Clinical diagnosis of liver abscess includes symptoms of fever, chills,
             right upper quadrant abdominal pain or knocking tenderness.

          -  Read, understood and signed informed consent form.

        Exclusion Criteria:

          -  Presence of septic metastatic infections to the CNS or eye at presentation.

          -  Cultures positive for an organism resistant to study drugs.

          -  APACHE II score greater or equal to 20.

          -  Co-existent disease considered likely to affect the outcome of the study (e.g.,
             biliary tract stones and malignancy).

          -  Patients with ruptured liver abscess

          -  Severe hepatic insufficiency (Child-Pugh C) or elevated serum transaminases (GPT) to
             greater than 5 times the upper limit of normal.

          -  Patients who are pregnant or lactating.

          -  Known hypersensitivity to b-lactams or fluoroquinolones.

          -  Known prolongation of the QT interval.

          -  Patients with uncorrected hypokalemia.

          -  Patients receiving class IA (e.g., quinidine, procainamide) or class III (e.g.,
             amiodarone, sotalol) antiarrhythmic agents

          -  Severe, life-threatening disease with a life expectancy of less than 2 months.

          -  Pre-treatment with a systemic antibacterial agent for &gt; 24 hours prior to enrollment
             within 5 days prior to enrollment.

          -  Participated in any clinical investigational drug study within 4 weeks of screening.

          -  Previously entered in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Shin-Jung Lee, M.D., M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lee SS, Chen YS, Tsai HC, Wann SR, Lin HH, Huang CK, Liu YC. Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess. Clin Infect Dis. 2008 Sep 1;47(5):642-50. doi: 10.1086/590932.</citation>
    <PMID>18643760</PMID>
  </reference>
  <reference>
    <citation>Tsai FC, Huang YT, Chang LY, Wang JT. Pyogenic liver abscess as endemic disease, Taiwan. Emerg Infect Dis. 2008 Oct;14(10):1592-600. doi: 10.3201/eid1410.071254.</citation>
    <PMID>18826824</PMID>
  </reference>
  <reference>
    <citation>Liu YC, Cheng DL, Lin CL. Klebsiella pneumoniae liver abscess associated with septic endophthalmitis. Arch Intern Med. 1986 Oct;146(10):1913-6.</citation>
    <PMID>3532983</PMID>
  </reference>
  <reference>
    <citation>Chang FY, Chou MY. Comparison of pyogenic liver abscesses caused by Klebsiella pneumoniae and non-K. pneumoniae pathogens. J Formos Med Assoc. 1995 May;94(5):232-7.</citation>
    <PMID>7613255</PMID>
  </reference>
  <reference>
    <citation>Yu WL, Chan KS, Ko WC, Lee CC, Chuang YC. Lower prevalence of diabetes mellitus in patients with Klebsiella pneumoniae primary liver abscess caused by isolates of K1/K2 than with non-K1/K2 capsular serotypes. Clin Infect Dis. 2007 Dec 1;45(11):1529-30; author reply 1532-3.</citation>
    <PMID>17990242</PMID>
  </reference>
  <reference>
    <citation>Chung DR, Lee SS, Lee HR, Kim HB, Choi HJ, Eom JS, Kim JS, Choi YH, Lee JS, Chung MH, Kim YS, Lee H, Lee MS, Park CK; Korean Study Group for Liver Abscess. Emerging invasive liver abscess caused by K1 serotype Klebsiella pneumoniae in Korea. J Infect. 2007 Jun;54(6):578-83. Epub 2006 Dec 18.</citation>
    <PMID>17175028</PMID>
  </reference>
  <reference>
    <citation>Tan YM, Chee SP, Soo KC, Chow P. Ocular manifestations and complications of pyogenic liver abscess. World J Surg. 2004 Jan;28(1):38-42. Epub 2003 Nov 14.</citation>
    <PMID>14612992</PMID>
  </reference>
  <reference>
    <citation>Yeoh KG, Yap I, Wong ST, Wee A, Guan R, Kang JY. Tropical liver abscess. Postgrad Med J. 1997 Feb;73(856):89-92.</citation>
    <PMID>9122104</PMID>
  </reference>
  <reference>
    <citation>Okano H, Shiraki K, Inoue H, Kawakita T, Yamamoto N, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Nakano T. Clinicopathological analysis of liver abscess in Japan. Int J Mol Med. 2002 Nov;10(5):627-30.</citation>
    <PMID>12373305</PMID>
  </reference>
  <reference>
    <citation>Wiwanitkit V. Causative agents of liver abscess in HIV-seropositive patients: a 10-year case series in Thai hospitalized patients. Trop Doct. 2005 Apr;35(2):115-7.</citation>
    <PMID>15970044</PMID>
  </reference>
  <reference>
    <citation>Lederman ER, Crum NF. Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: an emerging disease with unique clinical characteristics. Am J Gastroenterol. 2005 Feb;100(2):322-31. Review.</citation>
    <PMID>15667489</PMID>
  </reference>
  <reference>
    <citation>Nadasy KA, Domiati-Saad R, Tribble MA. Invasive Klebsiella pneumoniae syndrome in North America. Clin Infect Dis. 2007 Aug 1;45(3):e25-8. Epub 2007 Jun 18.</citation>
    <PMID>17599300</PMID>
  </reference>
  <reference>
    <citation>Keynan Y, Karlowsky JA, Walus T, Rubinstein E. Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniae. Scand J Infect Dis. 2007;39(9):828-30.</citation>
    <PMID>17701725</PMID>
  </reference>
  <reference>
    <citation>Karama EM, Willermain F, Janssens X, Claus M, Van den Wijngaert S, Wang JT, Verougstraete C, Caspers L. Endogenous endophthalmitis complicating Klebsiella pneumoniae liver abscess in Europe: case report. Int Ophthalmol. 2008 Apr;28(2):111-3. Epub 2007 Aug 1.</citation>
    <PMID>17668150</PMID>
  </reference>
  <reference>
    <citation>Rahimian J, Wilson T, Oram V, Holzman RS. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis. 2004 Dec 1;39(11):1654-9. Epub 2004 Nov 9.</citation>
    <PMID>15578367</PMID>
  </reference>
  <reference>
    <citation>Harris PJ, Laczek JT, Polish RD, Fraser SL. Two cases of Klebsiella pneumoniae primary liver abscesses; an emerging clinical entity among diabetics. Hawaii Med J. 2005 Dec;64(12):306-7, 325.</citation>
    <PMID>16438021</PMID>
  </reference>
  <reference>
    <citation>Yu SC, Ho SS, Lau WY, Yeung DT, Yuen EH, Lee PS, Metreweli C. Treatment of pyogenic liver abscess: prospective randomized comparison of catheter drainage and needle aspiration. Hepatology. 2004 Apr;39(4):932-8.</citation>
    <PMID>15057896</PMID>
  </reference>
  <reference>
    <citation>Wang JH, Liu YC, Lee SS, Yen MY, Chen YS, Wang JH, Wann SR, Lin HH. Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis. 1998 Jun;26(6):1434-8.</citation>
    <PMID>9636876</PMID>
  </reference>
  <reference>
    <citation>Chen YW, Chen YS, Lee SS, Yen MY, Wann SR, Lin HH, Huang WK, Liu YC. A pilot study of oral fleroxacin once daily compared with conventional therapy in patients with pyogenic liver abscess. J Microbiol Immunol Infect. 2002 Sep;35(3):179-83.</citation>
    <PMID>12380791</PMID>
  </reference>
  <reference>
    <citation>Zerem E, Hadzic A. Sonographically guided percutaneous catheter drainage versus needle aspiration in the management of pyogenic liver abscess. AJR Am J Roentgenol. 2007 Sep;189(3):W138-42.</citation>
    <PMID>17715080</PMID>
  </reference>
  <reference>
    <citation>Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, Towne JB. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother. 2004 Mar;48(3):1012-6.</citation>
    <PMID>14982797</PMID>
  </reference>
  <reference>
    <citation>Chang SC, Fang CT, Hsueh PR, Chen YC, Luh KT. Klebsiella pneumoniae isolates causing liver abscess in Taiwan. Diagn Microbiol Infect Dis. 2000 Aug;37(4):279-84.</citation>
    <PMID>10974581</PMID>
  </reference>
  <reference>
    <citation>Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. J Microbiol Immunol Infect. 2001 Sep;34(3):178-84.</citation>
    <PMID>11605808</PMID>
  </reference>
  <reference>
    <citation>Cheng HP, Siu LK, Chang FY. Extended-spectrum cephalosporin compared to cefazolin for treatment of Klebsiella pneumoniae-caused liver abscess. Antimicrob Agents Chemother. 2003 Jul;47(7):2088-92.</citation>
    <PMID>12821451</PMID>
  </reference>
  <reference>
    <citation>Paterson DL. &quot;Collateral damage&quot; from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004 May 15;38 Suppl 4:S341-5.</citation>
    <PMID>15127367</PMID>
  </reference>
  <reference>
    <citation>Van Saene JJ, Van Saene HK, Geitz JN, Tarko-Smit NJ, Lerk CF. Quinolones and colonization resistance in human volunteers. Pharm Weekbl Sci. 1986 Feb 21;8(1):67-71.</citation>
    <PMID>2938072</PMID>
  </reference>
  <reference>
    <citation>de Vries-Hospers HG, Welling GW, van der Waaij D. Influence of quinolones on throat- and faecal flora of healthy volunteers. Pharm Weekbl Sci. 1987 Dec 11;9 Suppl:S41-4.</citation>
    <PMID>3438150</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2009</study_first_submitted>
  <study_first_submitted_qc>May 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2009</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Susan Shin-Jung Lee</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>liver abscess</keyword>
  <keyword>moxifloxacin</keyword>
  <keyword>ceftriaxone</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Liver Abscess</mesh_term>
    <mesh_term>Liver Abscess, Pyogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

